Synthetic Biologics, Inc. is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company’s lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C).
BaseClear BV is a contract research company offering a complete package of tailored services for metagenomics, genome analyses, microbial identification and typing, protein engineering and synthetic biology. BaseClear has extensive experience with metagenomics and genome analyses projects using Next Generation sequencing technologies such as Illumina HiSEQ, MiSEQ and PacBio RS II platforms. In addition BaseClear has a team of scientific specialists and bioinformatics who can assist you to help answer your research questions. Over the last 20 years, BaseClear has gained significant experience offering these services to its food technology and industrial biotech partners.